Clinical DevelopmentLast reviewed April 2026

Blinding(Blinding)

A clinical trial design technique where participants, investigators, or both are prevented from knowing which treatment each subject is receiving.

Usage Examples

The double-blind placebo-controlled Phase 3 trial used matched tablets with identical appearance and packaging.
An emergency unblinding for severe adverse event management was documented per protocol.

What is Blinding?

Blinding (also called masking) is a clinical trial design technique to reduce bias in outcome assessment and reporting. Common designs: single-blind (subjects unaware of treatment assignment), double-blind (both subjects and investigators unaware), triple-blind (subjects, investigators, and data analysts unaware). Open-label studies are unblinded by design.

Blinding requires appropriate matching placebo or comparator (visual appearance, taste, packaging), secure randomization and assignment systems, unblinding procedures for emergencies, and pre-specified analytical plans that don't require unblinding. ICH E9 and regulatory guidance emphasize that well-executed blinding is essential for the integrity of comparative trial results, particularly for subjective endpoints. Post-hoc unblinded analyses can invalidate study conclusions.

Regulatory Context

This term appears most often in clinical development workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside ICH E6, ICH E9, ICH E10.

FDAEMAPMDA

When This Matters

The double-blind placebo-controlled Phase 3 trial used matched tablets with identical appearance and packaging.
An emergency unblinding for severe adverse event management was documented per protocol.

Common Mistakes

Applying one-region clinical assumptions to global submission strategies.
Missing protocol-to-regulation traceability for pivotal studies.
Underestimating how regional guidance updates impact trial documentation.

Related Regulations

ICH E6ICH E9ICH E10

Frequently Asked Questions

When blinding is impossible (different dosing routes or schedules, surgical interventions, different adverse event profiles that would unblind), when the endpoint is objective (death, lab value), or for early-phase safety/PK studies. Open-label studies generally require more rigorous bias-control measures in data handling.

Single-blind: subjects don't know assignment; investigators do. Double-blind: neither subjects nor investigators know. Double-blind is preferred for bias control, especially with subjective endpoints. Single-blind is used when investigator awareness is necessary for safety monitoring.

Protocol-specified unblinding procedures must exist for medical emergencies requiring treatment knowledge, regulatory safety reporting (SUSARs), and planned interim analyses. Unblinding events are logged, investigated for their effect on study integrity, and reported in the clinical study report.